Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Sep;110(1):442–446. doi: 10.1111/j.1476-5381.1993.tb13830.x

The beta-adrenoceptors mediating relaxation of rat oesophageal muscularis mucosae are predominantly of the beta 3-, but also of the beta 2-subtype.

R E de Boer 1, F Brouwer 1, J Zaagsma 1
PMCID: PMC2175964  PMID: 8106109

Abstract

1. beta-Adrenoceptor-mediated relaxation of rat oesophageal smooth muscle was investigated by studying the effects of beta 1- and beta 2-selective antagonists on the relaxation induced by (-)-isoprenaline, the beta 2-selective agonists fenoterol and clenbuterol and the beta 3-agonist, BRL 37344. 2. The highly beta 1-selective antagonist CGP 20721A did not antagonize (-)-isoprenaline- or BRL 37344-induced relaxations in concentrations up to 10 microM. Only at 100 microM of CGP 20712A were clear rightward shifts of the agonist concentration-response curves (CRCs) observed, with pA2 values of 4.70 and 4.97 against (-)-isoprenaline and BRL 37344, respectively. 3. ICI 118,551, a potent and selective beta 2-antagonist, at 100 nM caused moderate rightward shifts of the CRCs of (-)-isoprenaline, fenoterol and clenbuterol; with fenoterol and clenbuterol, this was accompanied by a clear steepening of the curve. Only at the highest concentration (100 microM ICI 118,551) did the shifts to the right further increase substantially. Resulting Schild-plots were clearly biphasic. BRL 37344-induced relaxations were only antagonized at 100 microM ICI 118,551, yielding a pA2 value of 5.48. 4. These results clearly demonstrate that the BRL 37344-induced relaxation of rat oesophageal muscularis mucosae is mediated solely through beta 3-adrenoceptors, whereas (-)-isoprenaline-, fenoterol- and clenbuterol-induced relaxations were shown to involve both beta 2- and, predominantly, beta 3-adrenoceptors.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arch J. R., Ainsworth A. T., Cawthorne M. A., Piercy V., Sennitt M. V., Thody V. E., Wilson C., Wilson S. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature. 1984 May 10;309(5964):163–165. doi: 10.1038/309163a0. [DOI] [PubMed] [Google Scholar]
  3. Bojanic D., Jansen J. D., Nahorski S. R., Zaagsma J. Atypical characteristics of the beta-adrenoceptor mediating cyclic AMP generation and lipolysis in the rat adipocyte. Br J Pharmacol. 1985 Jan;84(1):131–137. [PMC free article] [PubMed] [Google Scholar]
  4. Bond R. A., Clarke D. E. Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the alpha- and beta-subtypes. Br J Pharmacol. 1988 Nov;95(3):723–734. doi: 10.1111/j.1476-5381.1988.tb11698.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Buckner C. K., Christopherson R. C. Adrenergic receptors of rat esophageal smooth muscle. J Pharmacol Exp Ther. 1974 May;189(2):467–475. [PubMed] [Google Scholar]
  6. Challiss R. A., Leighton B., Wilson S., Thurlby P. L., Arch J. R. An investigation of the beta-adrenoceptor that mediates metabolic responses to the novel agonist BRL28410 in rat soleus muscle. Biochem Pharmacol. 1988 Mar 1;37(5):947–950. doi: 10.1016/0006-2952(88)90186-4. [DOI] [PubMed] [Google Scholar]
  7. Croci T., Cecchi R., Tarantino A., Aureggi G., Bianchetti A., Boigegrain R., Manara L. Inhibition of rat colon motility by stimulation of atypical beta-adrenoceptors with new gut-specific agents. Pharmacol Res Commun. 1988 Feb;20(2):147–151. doi: 10.1016/s0031-6989(88)80007-9. [DOI] [PubMed] [Google Scholar]
  8. Dooley D. J., Bittiger H., Reymann N. C. CGP 20712 A: a useful tool for quantitating beta 1- and beta 2-adrenoceptors. Eur J Pharmacol. 1986 Oct 14;130(1-2):137–139. doi: 10.1016/0014-2999(86)90193-7. [DOI] [PubMed] [Google Scholar]
  9. Emorine L. J., Feve B., Pairault J., Briend-Sutren M. M., Marullo S., Delavier-Klutchko C., Strosberg D. A. Structural basis for functional diversity of beta 1-, beta 2- and beta 3-adrenergic receptors. 1991 Mar 15-Apr 1Biochem Pharmacol. 41(6-7):853–859. doi: 10.1016/0006-2952(91)90188-b. [DOI] [PubMed] [Google Scholar]
  10. Emorine L. J., Marullo S., Briend-Sutren M. M., Patey G., Tate K., Delavier-Klutchko C., Strosberg A. D. Molecular characterization of the human beta 3-adrenergic receptor. Science. 1989 Sep 8;245(4922):1118–1121. doi: 10.1126/science.2570461. [DOI] [PubMed] [Google Scholar]
  11. Granneman J. G., Lahners K. N., Chaudhry A. Molecular cloning and expression of the rat beta 3-adrenergic receptor. Mol Pharmacol. 1991 Dec;40(6):895–899. [PubMed] [Google Scholar]
  12. Harms H. H., Zaagsma J., de Vente J. Differentiation of beta-adrenoceptors in right atrium, diaphragm and adipose tissue of the rat, using stereoisomers of propranolol, alprenolol, nifenalol and practolol. Life Sci. 1977 Jul 1;21(1):123–128. doi: 10.1016/0024-3205(77)90432-5. [DOI] [PubMed] [Google Scholar]
  13. Hausdorff W. P., Caron M. G., Lefkowitz R. J. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J. 1990 Aug;4(11):2881–2889. [PubMed] [Google Scholar]
  14. Hollenga C., Brouwer F., Zaagsma J. Relationship between lipolysis and cyclic AMP generation mediated by atypical beta-adrenoceptors in rat adipocytes. Br J Pharmacol. 1991 Mar;102(3):577–580. doi: 10.1111/j.1476-5381.1991.tb12215.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hollenga C., Haas M., Deinum J. T., Zaagsma J. Discrepancies in lipolytic activities induced by beta-adrenoceptor agonists in human and rat adipocytes. Horm Metab Res. 1990 Jan;22(1):17–21. doi: 10.1055/s-2007-1004839. [DOI] [PubMed] [Google Scholar]
  16. Hollenga C., Zaagsma J. Direct evidence for the atypical nature of functional beta-adrenoceptors in rat adipocytes. Br J Pharmacol. 1989 Dec;98(4):1420–1424. doi: 10.1111/j.1476-5381.1989.tb12692.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. MacKay D. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J Pharm Pharmacol. 1978 May;30(5):312–313. doi: 10.1111/j.2042-7158.1978.tb13237.x. [DOI] [PubMed] [Google Scholar]
  18. McLaughlin D. P., MacDonald A. Characterization of catecholamine-mediated relaxations in rat isolated gastric fundus: evidence for an atypical beta-adrenoceptor. Br J Pharmacol. 1991 Jun;103(2):1351–1356. doi: 10.1111/j.1476-5381.1991.tb09792.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. McLaughlin D. P., MacDonald A. Evidence for the existence of 'atypical' beta-adrenoceptors (beta 3-adrenoceptors) mediating relaxation in the rat distal colon in vitro. Br J Pharmacol. 1990 Nov;101(3):569–574. doi: 10.1111/j.1476-5381.1990.tb14122.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Van Amsterdam R. G., Meurs H., Brouwer F., Postema J. B., Timmermans A., Zaagsma J. Role of phosphoinositide metabolism in functional antagonism of airway smooth muscle contraction by beta-adrenoceptor agonists. Eur J Pharmacol. 1989 May 11;172(2):175–183. doi: 10.1016/0922-4106(89)90008-4. [DOI] [PubMed] [Google Scholar]
  21. Webber S. E., Stock M. J. Evidence for an atypical, or beta 3-adrenoceptor in ferret tracheal epithelium. Br J Pharmacol. 1992 Apr;105(4):857–862. doi: 10.1111/j.1476-5381.1992.tb09068.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Zaagsma J., Nahorski S. R. Is the adipocyte beta-adrenoceptor a prototype for the recently cloned atypical 'beta 3-adrenoceptor'? Trends Pharmacol Sci. 1990 Jan;11(1):3–7. doi: 10.1016/0165-6147(90)90032-4. [DOI] [PubMed] [Google Scholar]
  23. van der Vliet A., Rademaker B., Bast A. A beta adrenoceptor with atypical characteristics is involved in the relaxation of the rat small intestine. J Pharmacol Exp Ther. 1990 Oct;255(1):218–226. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES